TMEM97 is correlated with the clinical features and clinical prognosis, and acts as a potential marker of multiple myeloma

Abstract

Background: TMEM97 has been proven to be involved in many biological processes of malignancies. This study was designed to investigate the role of TMEM97 in multiple myeloma progression and clinical features and prognosis. We also predicted the potential mechanism of TMEM97 in MM prognosis.

Methods: In the present study, five GEO datasets including GSE24080, GSE13591, GSE2113, GSE19784 and GSE2658 were obtained from the National Cancer for Biotechnology Information database for analysis of TMEM97 expression and clinical features and prognosis in MM.We performed GSEA analysis to investigate the potential mechanism of TMEM97 in MM.

Results: We collected multiple myeloma data based on GEO datasets, and demonstrated the expression level of TMEM97 increased with the progression of multiple myeloma. Also the expression level of TMEM97 was correlated significantly with ISS stage in MM patients.Additionally, TMEM97 was more likely to be associated with important factors of MM prognosis, such as cytogenetic, B2M, CRP, LDH, BMPC, MRI and HGB. The multivariate analysis showed that TMEM97 was an independent factor for OS and EFS. In addition, top positively correlated genes with TMEM97 covered PUS7, GGCT, PFAS, CTPS1, RFC4 and PRMT3.

Conclusion:The expression of TMEM97 was a factor affecting the survival and prognosis of MM patients. TMEM97 may be an important prognosis biomarker and promising therapeutic target in multiple myeloma.